JP2011518811A - シグマ受容体阻害剤として有用な５−メチル−１−（ナフタレン−２−イル）−１ｈ−ピラゾール - Google Patents

シグマ受容体阻害剤として有用な５−メチル−１−（ナフタレン−２−イル）−１ｈ−ピラゾール Download PDF

Info

Publication number
JP2011518811A
JP2011518811A JP2011505534A JP2011505534A JP2011518811A JP 2011518811 A JP2011518811 A JP 2011518811A JP 2011505534 A JP2011505534 A JP 2011505534A JP 2011505534 A JP2011505534 A JP 2011505534A JP 2011518811 A JP2011518811 A JP 2011518811A
Authority
JP
Japan
Prior art keywords
compound
formula
methyl
pyrazol
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011505534A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011518811A5 (enExample
Inventor
ジョバー アントニ トレンス
マリア ロサ クベレス−アルティセント
サンチェス マリア ホセ プレテル
ヘラベルト マリア マグダレナ ボルダス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Pharmaceuticals SA
Original Assignee
Esteve Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Pharmaceuticals SA filed Critical Esteve Pharmaceuticals SA
Publication of JP2011518811A publication Critical patent/JP2011518811A/ja
Publication of JP2011518811A5 publication Critical patent/JP2011518811A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2011505534A 2008-04-25 2009-04-27 シグマ受容体阻害剤として有用な５−メチル−１−（ナフタレン−２−イル）−１ｈ−ピラゾール Pending JP2011518811A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08384005A EP2113501A1 (en) 2008-04-25 2008-04-25 5-Methyl-1-(naphthalen-2-YL)-1H-Pyrazoles useful as sigma receptor inhibitors
EP08384005.8 2008-04-25
PCT/EP2009/055065 WO2009130331A1 (en) 2008-04-25 2009-04-27 5-methyl-1-(naphthalen-2-yl)-1h-pyrazoles useful as sigma receptor inhibitors

Publications (2)

Publication Number Publication Date
JP2011518811A true JP2011518811A (ja) 2011-06-30
JP2011518811A5 JP2011518811A5 (enExample) 2012-06-07

Family

ID=39739580

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011505534A Pending JP2011518811A (ja) 2008-04-25 2009-04-27 シグマ受容体阻害剤として有用な５−メチル−１−（ナフタレン−２−イル）−１ｈ−ピラゾール

Country Status (11)

Country Link
US (1) US8492425B2 (enExample)
EP (2) EP2113501A1 (enExample)
JP (1) JP2011518811A (enExample)
KR (1) KR20110006697A (enExample)
CN (1) CN102066333A (enExample)
AU (1) AU2009239906A1 (enExample)
BR (1) BRPI0910679A2 (enExample)
CA (1) CA2722256A1 (enExample)
MX (1) MX2010011674A (enExample)
RU (1) RU2010147918A (enExample)
WO (1) WO2009130331A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
HRP20161128T1 (hr) * 2009-11-25 2016-11-18 Laboratorios Del Dr. Esteve, S.A. Hidrokloridna sol 4-[2-[[5-metil-1-(2-naftalenil)-1h-pirazol-3-il]oksi]etil]morfolina
EP2361904A1 (en) * 2010-02-04 2011-08-31 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride and crystalline forms thereof
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
PL2531177T3 (pl) * 2010-02-04 2016-11-30 Chlorowodorek 4-[2-[[5-metylo-1-(2-naftalenylo)-1h-pirazol-3-ilo]oksy]etylo]morfoliny i solwaty
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2395003A1 (en) 2010-05-27 2011-12-14 Laboratorios Del. Dr. Esteve, S.A. Pyrazole compounds as sigma receptor inhibitors
EP2418192A1 (en) * 2010-07-30 2012-02-15 Esteve Química, S.A. Intermediates for the preparation of 1-aryl-pyrazol-3-one compounds useful as sigma receptors inhibitors
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2426111A1 (en) * 2010-08-09 2012-03-07 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms
EP2460804A1 (en) * 2010-12-03 2012-06-06 Laboratorios Del Dr. Esteve, S.A. 5-methyl-1-(naphthalen-2-yl)-1h-pyrazole derivatives and their use in potentiating the effect of opioid analgesics
EP2460519A1 (en) 2010-12-03 2012-06-06 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in bone cancer pain
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
EP2818166A1 (en) * 2013-06-26 2014-12-31 Laboratorios del Dr. Esteve S.A. Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS)
SG11201604480PA (en) 2013-12-17 2016-07-28 Esteve Labor Dr SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS
JP6654633B2 (ja) 2014-08-01 2020-02-26 スマート ビリヤード ライティング エルエルシー ビリヤードテーブル照明及びゲームプレイモニタ
MA41177A (fr) * 2014-12-15 2017-10-24 Esteve Labor Dr Utilisation de ligands des récepteurs sigma dans l'arthrose
EP4475970A4 (en) 2022-02-09 2025-05-14 Martin, Blake Robert Interactive led system for enhancing billiard gameplay

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007098953A1 (en) * 2006-03-01 2007-09-07 Laboratorios Del Dr. Esteve, S.A. Pyrazole derivatives as sigma receptor inhibitors
JP2008510767A (ja) * 2004-08-27 2008-04-10 ラボラトリオス デル ドクトール エステベ エセ．ア． シグマ受容体阻害剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
EP1634872A1 (en) * 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Pyrazole derivatives as sigma receptor inhibitors
EP1829875A1 (en) * 2006-03-01 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Pyrazole derivatives as sigma receptor inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008510767A (ja) * 2004-08-27 2008-04-10 ラボラトリオス デル ドクトール エステベ エセ．ア． シグマ受容体阻害剤
WO2007098953A1 (en) * 2006-03-01 2007-09-07 Laboratorios Del Dr. Esteve, S.A. Pyrazole derivatives as sigma receptor inhibitors

Also Published As

Publication number Publication date
EP2285781A1 (en) 2011-02-23
WO2009130331A1 (en) 2009-10-29
EP2113501A1 (en) 2009-11-04
RU2010147918A (ru) 2012-05-27
KR20110006697A (ko) 2011-01-20
CN102066333A (zh) 2011-05-18
US8492425B2 (en) 2013-07-23
MX2010011674A (es) 2010-11-25
BRPI0910679A2 (pt) 2015-09-29
US20110118253A1 (en) 2011-05-19
AU2009239906A1 (en) 2009-10-29
CA2722256A1 (en) 2009-10-29

Similar Documents

Publication Publication Date Title
JP2011518811A (ja) シグマ受容体阻害剤として有用な５−メチル−１−（ナフタレン−２−イル）−１ｈ−ピラゾール
DE60219292T2 (de) Pyrazolderivate zur behandlung von hiv
CA2166721C (en) Bicyclic tetrahydro pyrazolopyridines
IL178882A (en) Tetrahydronaphthyridine derivatives useful as histamine h3 receptor ligands
EP0612319A1 (en) Benzoheterocyclic compounds as oxytocin and vasopressin antagonists
WO2007091152A1 (en) Triazolopyridine compounds
WO2007114323A1 (ja) アミノピロリジン化合物
JP5431305B2 (ja) 高速解離性ドパミン２受容体アンタゴニストとしての４−アルコキシピリダジン誘導体
US8895562B2 (en) Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists
AU2010247212B2 (en) 5-membered heterocyclic compound cyclopenta[c]pyrrolylalkylcarbamate derivatives, preparation thereof, and therapeutic use thereof
JP5255568B2 (ja) 迅速に解離するドーパミン２受容体アンタゴニストとしてのピペリジニルアミノ−ピリダジンおよびそれらの使用
KR20100097077A (ko) Ｈｓｐ90에 대한 억제 효능을 갖는 피리디논 유도체
KR20080067355A (ko) 염증 치료에 유용한 피라졸
Seo et al. Synthesis and structure–activity relationship of 1, 2, 4-triazole-containing diarylpyrazolyl carboxamide as CB1 cannabinoid receptor–ligand
WO2023017451A1 (en) Small molecule sting antagonists
EP3285760A1 (en) Pde10 inhibitors and related compositions and methods
EP1846409A1 (en) Octahydropyrrolo[3,4-c]pyrrole derivatives
DE60319254T2 (de) Pyrazolamide zur behandlung von hiv-infektionen
WO2007045989A1 (en) Pyridyl derivatives useful as h3 ligands
CA2497333A1 (en) Pyrazole derivatives as reverse transcriptase inhibitors
WO2021240423A1 (en) Dihydroorotate dehydrogenase inhibitors
MXPA05003641A (es) Derivados de pirazol y su uso como agentes terapeuticos para enfermedades mediadas por el virus de la inmunodeficiencia humana.
CN120187429A (zh) 转录因子eb激活因子及其用途
EP1671972A1 (en) Octahydropyrrolo[3,4-c]pyrrole derivatives
HK1184442A (en) Pyrazole compounds as sigma receptor inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120410

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120410

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131008

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140304